New Flu Vaccine for Children
Pharmacists in the community can now offer influenza nasal spray vaccine to children and adolescents on a private basis. The NHS started to vaccinate 2 and 3 year olds with this same vaccine in the last few weeks. The vaccine provides protection for the flu season 2013/14 and is suitable for children up to the age of 18 years.
Pharmacists administer the vaccine by spray into each nostril. No injection is necessary. The vaccine takes about 2 weeks to become effective and provides 60% to 100% protection. The nasal spray vaccine, called Fluenz, is a new type of vaccine for flu. Fluenz contains live virus in a weakened form and can produce a very mild flu-like illness. More traditional flu vaccines, given by injection, contain virus material that is not active and cannot cause an infection, even a mild one. The nasal spray vaccine provides better protection in children and adolescents, but is not recommended in adults, where it is a less effective vaccine.
During the coming years the NHS plans to extend annual flu vaccination to all younger school age children. This, it is hoped, will reduce illness in children, but also reduce the transmission of flu through communities. Children are known as super-vectors for the flu, as they tend to have multiple contacts and spread flu infection quickly.
Children who are in contact with severely immunocompromised people are not candidates for Fluenz, as they might spread the weakened virus in the vaccine to vulnerable people.
Pharmacists provide Fluenz vaccination on a private basis. Older children, over 16 years, can self-refer. In most cases parents of younger children will be the ones to decide whether to vaccinate their children. At the moment until NHS funding is available, in most cases, Fluenz vaccination for children over 5 years can only be administered privately with patients or their parents making a payment. The fee is set by pharmacies. In coming years the NHS may sponsor pharmacists to administer the vaccine.
Pharmacists are allowed to administer Fluenz Vaccine, which is normally a prescription only medicine, by a using a set of instructions called a Patient Group Direction (PGD). The PGD specifies which children are eligible for vaccination and which children are excluded. Children with severe asthma or some other medical problems are not eligible. Pharmacists receive specialist training before they are permitted to administer the new nasal spray vaccine. The PGD is provided by Red Box Healthcare Ltd through its website pharmacypgd.co.uk. Red Box is the largest provider of PGDs for community pharmacies and is not making a charge for pharmacists to use the new PGD.
Pharmacists can, by arrangement, administer Fluenz to children in schools through the PGD.
Pharmacist can now offer parents the choice to vaccinate their children against flu, where they might not currently have the option through the NHS.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance